BioNeex

The first Biopharma R&D open Exchange Platform for Licensing and Co-Development Partnerships of Drug Candidates

[BioNeex @BioNeex_]

Are you a development-stage biotech company and looking for licensing or co-development partners for your drug candidates?
Then list them for FREE on @BioNeex_ and get contacted directly by your potential partners.

#biopharma #biotech #pharma #biopharmaceutical

[BioNeex @BioNeex_]

https://t.co/IvfRwJBYWk

[BioNeex @BioNeex_]

https://t.co/xRGyD31gTu

[BioNeex @BioNeex_]

A peptide-peptide nucleic acid composed of a cell-penetrating peptide conjugated to a gene target-specific antisense peptide nucleic acid sequence for improved delivery into the bacterial cytoplasm. https://t.co/B9aPY9ZGbI

[BioNeex @BioNeex_]

A therapeutic candidate developed through a novel DNA-based drug delivery and development platform. Simplified method to deliver and use the patient’s own cells to manufacture the required proteins, T-cells, and antibodies in vivo for cancers. https://t.co/SC76RAXkFl

[BioNeex @BioNeex_]

A cell-penetrating peptide conjugated to a gene target-specific antisense peptide nucleic acid sequence for improved delivery into the bacterial cytoplasm. https://t.co/s15RbXQZOz

#biotech, #Pharmaceuticals, #investors, #oncology, #Neurology, #hematology, #Immunology

[BioNeex @BioNeex_]

A dual acting NLRP3 protein inhibitor that through its mechanism of action can reduce/preclude neurotoxicity in the CNS and PNS, specifically created by chemotherapy. https://t.co/WEOxRknWu6

#biotech, #investors, #oncology, #Neurology, #hematology, #Immunology

[BioNeex @BioNeex_]

A TRPV1 receptor modulator with a proprietary formulation that contains purified synthetic cannabidiol with improved bioavailability and blood brain barrier transmission. https://t.co/bFUzlmot6D

#biotech, #investors, #oncology, #Neurology, #hematology, #Immunology

[BioNeex @BioNeex_]

A drug candidate with no adverse effects, based on a platform, which not only reduces but also prevents high levels of LDL cholesterol. https://t.co/j2qLR00r0F

#biotech, #Pharmaceuticals, #Science,#partnerships, #investors, #oncology, #Neurology, #hematology, #Immunology

[BioNeex @BioNeex_]

A gene therapy to treat vision loss caused by RPGRIP1 mutations uses the novel Anc80 vector technology that has a superior delivery profile compared to commonly used AAVs. https://t.co/45VqranWbT

#biotech, #investors, #oncology, #Neurology, #hematology, #Immunology

[BioNeex @BioNeex_]

A first-in-class allogeneic innate cell therapy with promising human data showing 80% tumour necrosis in end-stage carcinoma patients at low dose. https://t.co/duJx9L3XGT

#biotech, #Pharmaceuticals, #partnerships, #investors, #oncology, #Neurology, #hematology, #Immunology

[BioNeex @BioNeex_]

A first-in-class antibiotic in the preclinical stage for drug-resistant Gram-negative pathogens, including N. gonorrhoeae and Pseudomonas aeruginosa. https://t.co/YVsSnp2VRg

#biotech, #Pharmaceuticals, #partnerships, #investors, #oncology, #Neurology, #hematology, #Immunology

[BioNeex @BioNeex_]

A non-antibiotic drug candidate for bacterial infections, which blocks the formation of disease-causing toxins without killing the pathogen and inhibits biofilm formation. https://t.co/1DUXQSJUMi

#biotech, #investors, #oncology, #Neurology, #hematology, #Immunology

[BioNeex @BioNeex_]

Cancer vaccine based on proprietary preparation of a protozoan, considered non-pathogenic to humans that overcomes the local cancer defenses of the Tumor Microenvironment. https://t.co/JryHm8A5AE

#biotech, #investors, #oncology, #Neurology, #hematology, #Immunology

[BioNeex @BioNeex_]

A novel cancer vaccine based on proprietary preparation of modified protozoan that replicates in tumor cells and secretes anti-cancer cytokine, human Interleukin-15. https://t.co/mpqmZNhoSb

#biotech, #Pharmaceuticals, #Science, #oncology, #Neurology, #hematology, #Immunology

[BioNeex @BioNeex_]

A modified non-pathogenic protozoan that restores immune competence in the tumor microenvironment and provokes potent anti-cancer immune response. https://t.co/agPNjt57g6

#biotech, #Pharmaceuticals,#partnerships, #investors, #oncology, #Neurology, #hematology, #Immunology

[BioNeex @BioNeex_]

A glycooptimized recombinant follicle-stimulating hormone produced by proprietary platform. It combines safety of recombinant production and human glycosylation. https://t.co/XTSmnzJ3jX

#biotech, #Science,#partnerships, #investors,#oncology, #Neurology, #hematology, #Immunology

[BioNeex @BioNeex_]

A drug candidate, consisting of a human cell expression system, which offers advantages over recombinant FVIIa forms like missing immunogenic glycan structures. https://t.co/wWxUoJa3NS

#biotech, #partnerships, #investors, #oncology, #Neurology, #hematology, #Immunology

[BioNeex @BioNeex_]

A novel drug candidate, designed to retain all Fv-mediated anti-tumor activities, largely improve anti-tumor efficacy via ADCC and reduce side effects. https://t.co/GVDV4aH0pv

#biotech, #Pharmaceuticals, #partnerships, #investors, #oncology, #Neurology, #hematology, #Immunology

[BioNeex @BioNeex_]

A novel drug candidate, designed to retain all Fv-mediated anti-tumor activities, largely improve anti-tumor efficacy via ADCC and reduce side effects. https://t.co/GVDV4aH0pv

#biotech, #Pharmaceuticals, #partnerships, #investors, #oncology, #Neurology, #hematology, #Immunology

[BioNeex @BioNeex_]

A glycooptimized anti-PD-L1 monoclonal antibody that combines strong inhibition of the PD1/PD-L1 interaction with improved T cell re-activation. https://t.co/fUPPbDaRK1

#biotech, #Pharmaceuticals, #Science,#partnerships, #investors, #oncology,#Neurology, #hematology,#Immunology